Publicacións (281) Publicacións de JUAN FRANCISCO ASCASO GIMILIO

2023

  1. Atherogenic dyslipidaemia in type 2 diabetes mellitus: The PREDISAT study

    Lipids, Vol. 58, Núm. 4, pp. 197-206

2022

  1. Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players

    Biomedicine and Pharmacotherapy, Vol. 145

  2. Corticotroph cell hyperplasia as a rare cause of ACTH-dependent Cushing syndrome

    Endocrinologia, Diabetes y Nutricion, Vol. 69, Núm. 9, pp. 694-701

2021

  1. Hypotriglyceridemias/hypolipidemias

    Clinica e Investigacion en Arteriosclerosis, Vol. 33, pp. 63-68

  2. Lipid metabolism and classification of hyperlipaemias

    Clinica e Investigacion en Arteriosclerosis, Vol. 33, pp. 3-9

  3. Oral Unsaturated Fat Load Impairs Postprandial Systemic Inflammation in Primary Hypercholesterolemia Patients

    Frontiers in Pharmacology, Vol. 12

  4. Peripheral blood levels of CXCL10 are a useful marker for diabetic polyneuropathy in subjects with type 2 diabetes

    International Journal of Clinical Practice, Vol. 75, Núm. 8

  5. Postprandial triglyceridaemia is modulated by insulin resistance but not by grade of obesity in abdominal and morbid obese subjects

    International Journal of Clinical Practice, Vol. 75, Núm. 4

2020

  1. Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis Society

    Clinica e Investigacion en Arteriosclerosis, Vol. 32, Núm. 3, pp. 120-125

  2. Chronic kidney disease as a cardiovascular risk factor

    Journal of hypertension, Vol. 38, Núm. 11, pp. 2110-2121

  3. Clinical and genetic differences between heterozygous familial hypercholesterolemia patients with and without type 2 diabetes

    Revista Espanola de Cardiologia, Vol. 73, Núm. 9, pp. 718-724

  4. Gender differences on oxidative stress markers and complement component C3 plasma values after an oral unsaturated fat load test

    Clínica e investigación en arteriosclerosis, Vol. 32, Núm. 3, pp. 87-93

  5. Gender differences on oxidative stress markers and complement component C3 plasma values after an oral unsaturated fat load test

    Clinica e Investigacion en Arteriosclerosis, Vol. 32, Núm. 3, pp. 87-93

  6. Triglicéridos, colesterol HDL y dislipidemia aterogénica en la guía europea para el control de las dislipidemias 2019

    Clínica e investigación en arteriosclerosis, Vol. 32, Núm. 5, pp. 209-218

  7. Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias

    Clinica e Investigacion en Arteriosclerosis, Vol. 32, Núm. 5, pp. 209-218

2019

  1. Changes in CDKN2A/2B expression associate with T-cell phenotype modulation in atherosclerosis and type 2 diabetes mellitus

    Translational Research, Vol. 203, pp. 31-48

  2. Control of the overall lipid profile

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, pp. 34-41

  3. Gene expression profile following an oral unsaturated fat load in abdominal obese subjects

    European Journal of Nutrition, Vol. 58, Núm. 3, pp. 1331-1337

  4. Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019

    Clínica e investigación en arteriosclerosis, Vol. 31, Núm. 3, pp. 128-139

  5. Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Sociey of Arteriosclerosis (SEA), 2019

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, Núm. 3, pp. 128-139